JPH04235942A - Granulation of powdery calcium acetate - Google Patents
Granulation of powdery calcium acetateInfo
- Publication number
- JPH04235942A JPH04235942A JP7025091A JP7025091A JPH04235942A JP H04235942 A JPH04235942 A JP H04235942A JP 7025091 A JP7025091 A JP 7025091A JP 7025091 A JP7025091 A JP 7025091A JP H04235942 A JPH04235942 A JP H04235942A
- Authority
- JP
- Japan
- Prior art keywords
- calcium acetate
- sieve
- granulation
- nominal size
- granulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 title claims abstract description 33
- 239000001639 calcium acetate Substances 0.000 title claims abstract description 33
- 229960005147 calcium acetate Drugs 0.000 title claims abstract description 33
- 235000011092 calcium acetate Nutrition 0.000 title claims abstract description 33
- 238000005469 granulation Methods 0.000 title claims abstract description 9
- 230000003179 granulation Effects 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000004898 kneading Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 14
- 239000008187 granular material Substances 0.000 abstract description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 7
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract description 5
- 239000003463 adsorbent Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000007605 air drying Methods 0.000 abstract description 2
- 238000004806 packaging method and process Methods 0.000 abstract description 2
- 238000005538 encapsulation Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000005991 hyperphosphatemia Diseases 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、粉末酢酸カルシウムの
顆粒化法に関し、さらに詳しくは慢性腎不全患者に対す
るリン酸の吸着剤として最適な粉末酢酸カルシウムの顆
粒化法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for granulating powdered calcium acetate, and more particularly to a method for granulating powdered calcium acetate, which is most suitable as an adsorbent for phosphoric acid for patients with chronic renal failure.
【０００２】0002
【従来の技術】従来、粉末酢酸カルシウムを顆粒化する
方法は存在しなかった。これは、そもそも粉末酢酸カル
シウム等のカルシウム塩は水和状態にて加圧により一旦
硬化が起こると元には戻らないという性質があり、その
ため顆粒化が困難であった。BACKGROUND OF THE INVENTION Hitherto, there has been no method for granulating powdered calcium acetate. This is because calcium salts such as powdered calcium acetate have a property that once they harden under pressure in a hydrated state, they do not return to their original state, which makes it difficult to granulate them.
【０００３】0003
【発明が解決しようとする課題】近年人工腎臓治療を受
けている慢性腎不全患者は我が国において約１０万名に
達している。このように多数存在する慢性腎不全患者は
、自らの力では腎臓からリン酸を***することができず
、また人工腎臓によるリン酸の***も不十分であったた
め、体内中のリン酸値が高まる高リン酸血症に罹患する
ことが多かった。従来この高リン酸血症の対策として、
食物中のリン酸を小腸から吸収するのを防止する目的で
水酸化アルミニウムゲルをリン酸の吸着剤として服用す
るが、この場合は水酸化アルミニウムゲル中のアルミニ
ウムは体内に蓄積してアルミニウム脳症（痴呆）やアル
ミニウム骨症（骨軟化症）を惹起していた。[Problems to be Solved by the Invention] In recent years, the number of chronic renal failure patients receiving artificial kidney treatment has reached approximately 100,000 in Japan. These many patients with chronic renal failure are unable to excrete phosphoric acid from their kidneys on their own, and the excretion of phosphoric acid by the artificial kidneys is also insufficient, resulting in low levels of phosphoric acid in the body. They often suffered from increased hyperphosphatemia. Conventionally, as a countermeasure for this hyperphosphatemia,
Aluminum hydroxide gel is taken as a phosphate adsorbent to prevent dietary phosphoric acid from being absorbed from the small intestine, but in this case, the aluminum in the aluminum hydroxide gel accumulates in the body, causing aluminum encephalopathy (aluminum encephalopathy). This caused dementia) and aluminum osteopathy (osteomalacia).
【０００４】このため本発明者等は、水酸化アルミニウ
ムの代わりに酢酸カルシウムをリン酸吸着剤として使用
することに着目した。酢酸カルシウムを使用する場合に
おいては、水酸化アルミニウムにおける前述のような問
題点は起こらない。一般に酢酸カルシウム等のカルシウ
ム塩は、粒子径が小さく、水和状態にて凝集性の強い粉
体であるため、処方箋実施の際の分包誤差が著しく、調
剤に非常に苦労しているのが現実である。我が国におい
て酢酸カルシウムは化学品として粉末状のもののみが製
造されており、錠剤やカプセル剤としての薬剤を製造し
たり、正確な分包をするというようなことは出来ず、か
つこれをそのまま服用するにしても粉末状であるため服
用しにくい等の問題点があった。本発明は、上記の問題
点を解消した粉末酢酸カルシウムの顆粒化法を提供しよ
うとするものである。For this reason, the present inventors focused on using calcium acetate as a phosphoric acid adsorbent instead of aluminum hydroxide. When calcium acetate is used, the aforementioned problems with aluminum hydroxide do not occur. In general, calcium salts such as calcium acetate have small particle diameters and are highly cohesive powders in a hydrated state, which causes significant packaging errors when filling prescriptions, making dispensing very difficult. It's reality. In Japan, calcium acetate is only manufactured in powder form as a chemical product, and it is not possible to manufacture drugs in the form of tablets or capsules or to package them accurately, and it is difficult to take them as they are. Even if it were, there were problems such as it being difficult to take because it was in powder form. The present invention aims to provide a method for granulating powdered calcium acetate that solves the above problems.
【０００５】[0005]
【課題を解決するための手段】このため本発明では粉末
酢酸カルシウムの粉砕工程と、粉末酢酸カルシウムを１
００重量部に対し水４０重量部を添加して練り合わせる
練合工程と、この練り合わされた酢酸カルシウムを所定
呼び寸法の篩を用いて押し出す造粒工程と、造粒された
酢酸カルシウムを室温で風乾する乾燥工程と、造粒工程
で用いた篩よりも目の細かい呼び寸法の篩で凝集粒子を
細分する細分工程とからなる粉末酢酸カルシウムの顆粒
化法をもって、課題解決のための手段とするものである
。[Means for Solving the Problems] Therefore, in the present invention, the powdered calcium acetate is pulverized and the powdered calcium acetate is
A kneading process in which 40 parts by weight of water is added to 00 parts by weight, a granulation process in which the kneaded calcium acetate is extruded using a sieve with a predetermined nominal size, and the granulated calcium acetate is mixed at room temperature. A method for granulating powdered calcium acetate, which consists of a drying process in which it is air-dried, and a subdivision process in which aggregated particles are subdivided using a sieve with a nominal size smaller than that used in the granulation process, is a means to solve the problem. It is something.
【０００６】[0006]
【実施例】以下、本発明の実施例を説明する。粉末を顆
粒化する方法としては、乾式顆粒化法と、湿式顆粒化法
の二種があり、何れも主薬を分級し賦形剤（乳糖、白糖
、ソルビット、澱粉等）・崩壊剤（澱粉、結晶セルロー
ス、カルボキシメチルセルロースカルシウム等）・結合
剤（ゼラチン、アラビアゴム、グルコース、カルボキシ
メチルセルロースナトリウム等）を加えて混合するのが
通常である。本発明は湿式顆粒化法に属し、水以外の添
加物を一切必要とせず、カルシウム塩の特性上造粒され
た顆粒は元の粉末には戻らない特徴がある。もちろん、
必要に応じて賦形剤・崩壊剤・矯味剤を加えて服用条件
を改善することは可能である。[Examples] Examples of the present invention will be described below. There are two methods for granulating powder: dry granulation and wet granulation, both of which classify the active ingredient and add excipients (lactose, sucrose, sorbitol, starch, etc.) and disintegrants (starch, Usually, a binder (gelatin, gum arabic, glucose, sodium carboxymethylcellulose, etc.) is added and mixed. The present invention belongs to the wet granulation method and does not require any additives other than water, and due to the characteristics of the calcium salt, the granulated granules do not return to the original powder. of course,
It is possible to improve the dosing conditions by adding excipients, disintegrants, and flavoring agents as necessary.
【０００７】実施例１
１．酢酸カルシウム（Ｃａ（ＣＨ３ＣＯＯ）２・Ｈ２Ｏ
）を乳鉢中で可能な限り細かく粉砕し、必要に応じて８
０〜１００号（呼び寸法１７７〜１５０μｍ）篩を通す
（粉砕工程）。
２．酢酸カルシウムをボールに入れ、撹拌しながら均一
に万遍なく水を噴霧する。水の量は、室内湿度５０〜７
５％の条件下で酢酸カルシウム１０００ｇに対し、４０
０ｇとした。この状態で全体が顆粒状になるまで３〜５
分間練合した（練合工程）。
３．練合した酢酸カルシウムを１６号（呼び寸法１１９
０μｍ）篩を用いて、自然落下状態で押し出し造粒した
（造粒工程）。
４．造粒した酢酸カルシウムを模造紙上に薄く拡げ、４
５〜５０℃で風乾した（乾燥工程）。
５．顆粒を約８分通り乾燥したとき、２０号（呼び寸法
１０００μｍ）篩を通して凝集粒子を細分し、顆粒を十
分乾燥した後、８０号（呼び寸法１７７μｍ）篩で粉末
部分を除き、粉末は次のロット仕込み時に再利用する（
細分工程）。実施例１の結果は下記の表１に示す通りで
あった。Example 1 1. Calcium acetate (Ca(CH3COO)2・H2O
) in a mortar as finely as possible, and if necessary
Pass through a No. 0 to 100 (nominal size 177 to 150 μm) sieve (pulverization step). 2. Place calcium acetate in a bowl and spray water evenly and evenly while stirring. The amount of water is indoor humidity 50-7
40% for 1000g of calcium acetate under 5% condition.
It was set to 0g. 3 to 5 minutes in this state until the whole becomes granular.
The mixture was kneaded for a minute (kneading step). 3. Mixed calcium acetate No. 16 (nominal size 119)
Using a sieve (0 μm), the mixture was extruded and granulated in a natural falling state (granulation step). 4. Spread the granulated calcium acetate thinly on the paper and
It was air-dried at 5-50°C (drying step). 5. When the granules were dried for about 8 minutes, the agglomerated particles were finely divided through a No. 20 sieve (nominal size 1000 μm), and after the granules were thoroughly dried, the powder portion was removed using a No. 80 sieve (nominal size 177 μm). Reuse when preparing lots (
subdivision process). The results of Example 1 were as shown in Table 1 below.
【０００８】[0008]
【表１】[Table 1]
【０００９】製品（Ａ）が求める顆粒である場合、製品
（Ｂ）やロス分は、その後の連続製造時に他のロット分
に混入させることができる。実施例で示したように、少
量生産では主薬と水と顆粒化のための篩と主薬の練合の
ための乳鉢と、顆粒乾燥のための容器のみで十分であり
、造粒のポイントは添加すべき水の量的範囲と、練合の
時間的範囲並びにその均質さである。なお実施例では、
粉体の流動性の目安である安息角（粉体を堆積させると
きの粉体層の自由表面と水平面のなす角）が６０゜から
３７°に変化し、嵩密度が０．３１ｇ／ｍｌから０．５
２ｇ／ｍｌへと約１．７倍に増大して、充填性が向上し
非常に扱い易い顆粒になった。ここで安息角は、通常４
０〜３０°が扱い易く、５０°以上では流動性が大変低
下する。また加えられた水は風乾の過程でほとんど散失
し、原粉末とほぼ同じ含水率（約１０％）であることを
熱分析器で確認した。[0009] When the product (A) is the desired granule, the product (B) and the loss can be mixed into other lots during subsequent continuous production. As shown in the examples, for small-scale production, only the main ingredient, water, a sieve for granulating, a mortar for kneading the main ingredient, and a container for drying the granules are sufficient, and the key to granulation is the addition These are the quantitative range of water to be mixed, the temporal range of kneading, and its homogeneity. In addition, in the example,
The angle of repose (the angle between the free surface of the powder layer and the horizontal plane when depositing the powder), which is a measure of the fluidity of powder, changes from 60° to 37°, and the bulk density changes from 0.31 g/ml to 37°. 0.5
The granules were increased approximately 1.7 times to 2 g/ml, resulting in improved filling properties and very easy to handle granules. Here, the angle of repose is usually 4
0 to 30° is easy to handle, and if it is 50° or more, the fluidity decreases significantly. Furthermore, most of the added water was lost during the air-drying process, and it was confirmed using a thermal analyzer that the moisture content was almost the same as the original powder (approximately 10%).
【００１０】0010
【発明の効果】よって本発明は、顆粒化された酢酸カル
シウムの流動性が高まり、分包が極めて容易となり、酢
酸カルシウムをカプセルに封入したり錠剤化したりする
ことも簡単になり、慢性腎不全患者にとって直接服用す
ることも容易になる等のすぐれた効果がある。[Effects of the Invention] Therefore, the present invention improves the fluidity of granulated calcium acetate, makes it extremely easy to package, and makes it easy to encapsulate calcium acetate or make it into tablets. It has excellent effects such as making it easier for patients to take it directly.
Claims (1)
酸カルシウムを１００重量部に対し水４０重量部を添加
して練り合わせる練合工程と、この練り合わされた酢酸
カルシウムを所定呼び寸法の篩を用いて押し出す造粒工
程と、造粒された酢酸カルシウムを室温で風乾する乾燥
工程と、造粒工程で用いた篩よりも目の細かい呼び寸法
の篩で凝集粒子を細分する細分工程とからなる粉末酢酸
カルシウムの顆粒化法。Claim 1: A step of crushing powdered calcium acetate, a kneading step of adding and kneading 40 parts by weight of water to 100 parts by weight of powdered calcium acetate, and passing the kneaded calcium acetate through a sieve of a predetermined nominal size. A drying process in which the granulated calcium acetate is air-dried at room temperature, and a subdivision process in which the aggregated particles are subdivided using a sieve with a nominal size finer than the sieve used in the granulation process. Granulation method of powdered calcium acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7025091A JPH04235942A (en) | 1991-01-16 | 1991-01-16 | Granulation of powdery calcium acetate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7025091A JPH04235942A (en) | 1991-01-16 | 1991-01-16 | Granulation of powdery calcium acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04235942A true JPH04235942A (en) | 1992-08-25 |
Family
ID=13426129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7025091A Pending JPH04235942A (en) | 1991-01-16 | 1991-01-16 | Granulation of powdery calcium acetate |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04235942A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11130673A (en) * | 1997-10-31 | 1999-05-18 | Eisai Co Ltd | Extrusion-granulated composition |
| US7997703B2 (en) | 2003-03-26 | 2011-08-16 | Seiko Epson Corporation | Liquid container |
| US8563032B2 (en) * | 2005-12-05 | 2013-10-22 | Roxane Laboratories, Inc. | Formulation and manufacturing process for calcium acetate capsules |
| US8808735B2 (en) | 2005-02-03 | 2014-08-19 | Takeda Nycomed As | Fast wet-massing method for the preparation of calcium-containing compositions |
| JP2014200215A (en) * | 2013-04-08 | 2014-10-27 | 大東化学株式会社 | Food additive, calcium acetate powder, and manufacturing method thereof |
-
1991
- 1991-01-16 JP JP7025091A patent/JPH04235942A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11130673A (en) * | 1997-10-31 | 1999-05-18 | Eisai Co Ltd | Extrusion-granulated composition |
| US7997703B2 (en) | 2003-03-26 | 2011-08-16 | Seiko Epson Corporation | Liquid container |
| US8808735B2 (en) | 2005-02-03 | 2014-08-19 | Takeda Nycomed As | Fast wet-massing method for the preparation of calcium-containing compositions |
| US8563032B2 (en) * | 2005-12-05 | 2013-10-22 | Roxane Laboratories, Inc. | Formulation and manufacturing process for calcium acetate capsules |
| US9060951B2 (en) | 2005-12-05 | 2015-06-23 | Roxane Laboratories, Inc. | Formulation and manufacturing process for calcium acetate capsules |
| US10300020B2 (en) | 2005-12-05 | 2019-05-28 | West-Ward Pharmaceuticals International Limited | Formulation and manufacturing process for calcium acetate capsules |
| JP2014200215A (en) * | 2013-04-08 | 2014-10-27 | 大東化学株式会社 | Food additive, calcium acetate powder, and manufacturing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1213829A (en) | Spray-dried vitamin powders | |
| EP2151247B1 (en) | Solid dialysis preparation | |
| JP2009525316A5 (en) | ||
| US4675188A (en) | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting | |
| JPH0753663B2 (en) | Thiamine salt granules, their production and tablets | |
| EP0367056B1 (en) | A granulating composition and method | |
| JP2013048894A (en) | Dialysis agent and method for manufacturing the same | |
| JPH04235942A (en) | Granulation of powdery calcium acetate | |
| JP2002104956A (en) | Base for dry direct compressing hydroxypropylcellulose having low substitution degree | |
| JP3004758B2 (en) | Processed starch with excellent binding and disintegration properties | |
| CN105125575A (en) | Preparation method of drug for hyperphosphatemia | |
| JP2001114703A (en) | Solid medicine and method for producing the same | |
| JP2685275B2 (en) | Xylitol-based binding / diluting agent and method for producing the same | |
| JP4997741B2 (en) | Low melting point drug-containing powder and method for producing the same | |
| CN107468655B (en) | Lentinan particles and preparation method thereof | |
| JP4774739B2 (en) | Kampo extract-containing tablet composition and method for producing the same | |
| CN108324697B (en) | Mosapride citrate-containing capsule and preparation method thereof | |
| JPH05105636A (en) | Antacid agent composition | |
| CN112655969A (en) | Choline bitartrate granules, tablets containing same and preparation method | |
| US5236920A (en) | Granulated riboflavin product having high flowability, high riboflavin content | |
| JPS6236173A (en) | Formed solid material and production thereof | |
| JPS5966858A (en) | Granular salt | |
| JP2986256B2 (en) | Granules for hemodialysis | |
| CA1133830A (en) | Disodium cromoglycate formulation | |
| Zakowiecki et al. | Beyond just a filler–application of calcium phosphates in direct compression formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 19950919 |